Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.
As the Senate wraps up its final legislative days for the year, it is expected to vote on a bill affecting Social Security benefits for about 3 million people.